2013 Videos - Symposium Presentations

Part 1: Multidisciplinary panel to achieve the best possible outcome for mesothelioma patients

Moderator: Mary Hesdorffer, NP
Please see previous biography.

Michele Carbone, MD, PhD

Please see previous biography.

Marc de Perrot, MD, MSc, FRCSC

Dr. de Perrot obtained his Medical Degree at the University of Geneva in Switzerland and completed his training in Thoracic Surgery at the University of Toronto, Canada and University Paris-Sud in France. Dr de Perrot joined the faculty in the Division of Thoracic Surgery at the Toronto General Hospital and Princess Margaret Cancer Center in 2005 and is currently the head of the Toronto Mesothelioma Research Program. The Toronto Mesothelioma Research Program is the largest mesothelioma program in Canada and involves a large multidisciplinary group of clinicians and scientists. The program has an ongoing screening program for individuals exposed to asbestosis and an active translational research laboratory focusing on immunotherapy for mesothelioma.

David S. Ettinger, MD, FACP, FCCP

David S. Ettinger, MD, FACP, FCCP is the Alex Grass Professor of Oncology at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He is also a professor of medicine and radiation oncology and molecular radiation sciences. Dr. Ettinger received his medical degree from the University of Louisville, School of Medicine. He completed his medical internship and residency at the Albany Medical Center and Mayo Clinic, respectively. Dr. Ettinger completed his training in medical oncology at Johns Hopkins in 1975, and since then has been on the faculty of the School of Medicine. Dr. Ettinger is a member of the board of directors of the National Comprehensive Cancer Network (NCCN) as well as a member of the NCCN Guidelines Steering Committee. In addition, he has been chairman of the NCCN non–small cell lung cancer practice guidelines panel as well as mesothelioma and thymoma and thymic carcinoma guidelines panels. Dr. Ettinger’s research interests are in new drug development and innovative multidisciplinary treatment strategies in lung cancer and sarcomas. He is also interested in improving supportive care measures associated with cancer and its treatment. Dr. Ettinger has authored or co-authored over 200 articles and serves as an editor for Current Treatment Options in Oncology. He is a Board Member of the Mesothelioma Applied Research Foundation.

Hedy Lee Kindler, MD

Dr. Kindler is a Medical Oncologist and Director of the Mesothelioma Program of the University of Chicago. She is the Chair of the Mesothelioma Program in the Alliance for Clinical Trials in Oncology, a national clinical trials research group. Her research is focused on the evaluation of novel drugs for the treatment of pleural and peritoneal mesothelioma, including drugs that target the c-MET, PI3K, and EGFR signal transduction pathways.

Lee M. Krug, MD

Please see previous biography.

Charles B Simone, II, MD

Charles B. Simone, II, MD is an Assistant Professor in the Department of Radiation Oncology at the Hospital of the University of Pennsylvania. Dr. Simone completed his undergraduate training at the University of Pennsylvania and earned his medical degree from the Perelman School of Medicine of the University of Pennsylvania. Following completing his internship in internal medicine, he completed residency training in radiation oncology at the National Cancer Institute, National Institutes of Health. Dr. Simone treats patients with mesothelioma, lung cancer, and other thoracic malignancies with photon and proton radiation therapy and with photodynamic therapy. He performs clinical and translational research investigating the treatment of mesothelioma and other thoracic malignancies with photodynamic therapy, and he conducts clinical research investigating the use of radiation therapy as part of multi-modality therapy for mesothelioma and non-small cell and small cell lung cancers.



Part 2: Multidisciplinary panel to achieve the best possible outcome for mesothelioma patients

Moderator: Mary Hesdorffer, NP
Please see previous biography.

Michael J. Becich, MD, PhD

Michael J. Becich, MD, PhD, is Professor and Chairman of the Dept. of Biomedical Informatics, University of Pittsburgh School of Medicine Dr. Becich’s research interests are focused on the interface between clinical informatics and bioinformatics. His research is funded by the CDC/NIOSH, DOD/TATRC/USAMRMC, NCI, NCATS, NHLBI and NLM, and includes clinical phenotyping of patients for genome wide association studies/next generation sequencing, tissue banking informatics, clinical informatics and bioinformatics with a special emphasis on data sharing. He has a long track record of working with the military, particularly the Telemedicine and Advanced Technology Research Center (TATRC) and the US Army Medical Research Material Command (USAMRMC). He is the principal investigator of the National Mesothelioma Virtual Bank (NMVB) and University of Pittsburgh is the central coordinating center. NMVB is currently in the seventh year of funding from the National Institute of Occupational Safety and Health (NIOSH) of the Center for Disease Control (CDC) and is a partnership with the Mesothelioma Applied Research Foundation, Mount Sinai School of Medicine, New York University and the University of Pennsylvania. Dr. Becich and his team have been national leaders in tissue banking, honest broker practices, HIPAA compliant de-identification of clinical data and the accompanying biomedical informatics to enable translational research utilizing biospecimens.

V. Courtney Broaddus, MD

Michele Carbone, MD, PhD

Andrew Todd, PhD

Andy Todd is the Director of the Insulators’ Tissue Bank at Mount Sinai. He is originally a physicist from England where he graduated with his doctorate in 1989. He moved to the U.S. in 1990 and Mount Sinai in 1992. He is currently an Associate Professor in the Department of Preventive Medicine of the Icahn School of Medicine at Mount Sinai, and an Adjunct Associate Professor in the Bloomberg School of Public Health at Johns Hopkins. Andy was recruited by Mount Sinai to perform a novel technique to measure cumulative lead exposure using a very-low-dose x-ray procedure that was developed where he studied and which he further developed and deployed for many studies of occupational and non-occupational lead exposure, both throughout the U.S. and around the world. Andy was asked to help create and then direct almost all non-medical aspects of the World Trade Center Medical Screening (and Monitoring) Programs at Mount Sinai for ~30,000 (non-FDNY) rescue and recovery workers, an undertaking that required enormous effort, attention to myriad details, and organization. This became the IAHFIAW’s vision for a tissue bank for their members to accelerate the research into the detection, treatment and cure of asbestos-related illness disproportionately suffered by the IAHFIAW membership.

Lee M. Krug, MD

 

 



Meso Foundation: Who we are and what we do | Mary Hesdorffer, NP

Mary Hesdorffer, NP

Mary Hesdorffer received her undergraduate degree at the College of New Rochelle in NY and went on to receive her Masters of Science at the same institution. She is fully credentialed as a Nurse Practitioner and has spent 15 years actively treating patients with mesothelioma. Mary has an expertise in the development and implementation of clinical trials. She has published in peer reviewed journals and has lectured nationally on the topics pertaining to mesothelioma with particular emphasis on clinical trials as well as symptom and disease management. Mary has been a strong voice in urging increased transparency to the medical and legal issues surrounding mesothelioma with a strong emphasis on ethics. She is passionate in her commitment to the treatment and management of this disease and hopes to increase awareness of the need to advance the science that will lead to a cure. She is available via phone or email to assist patients and caregivers as they move from chaos to control of this new situation they find themselves thrust into.



Information for New Patients | Mary Hesdorffer, Executive Director

Mary Hesdorffer, NP

Mary Hesdorffer received her undergraduate degree at the College of New Rochelle in NY and went on to receive her Masters of Science at the same institution. She is fully credentialed as a Nurse Practitioner and has spent 15 years actively treating patients with mesothelioma. Mary has an expertise in the development and implementation of clinical trials. She has published in peer reviewed journals and has lectured nationally on the topics pertaining to mesothelioma with particular emphasis on clinical trials as well as symptom and disease management. Mary has been a strong voice in urging increased transparency to the medical and legal issues surrounding mesothelioma with a strong emphasis on ethics. She is passionate in her commitment to the treatment and management of this disease and hopes to increase awareness of the need to advance the science that will lead to a cure. She is available via phone or email to assist patients and caregivers as they move from chaos to control of this new situation they find themselves thrust into.



Value, Worth and Merit of the Meso Foundation | Melinda Kotzian, COO

Melinda Kotzian, COO, Meso Foundation

Melinda Kotzian came to the Meso Foundation with a wide range of experience in the foundation world. She has a wide range of job duties including managing the day to day functions of the Meso Foundation, organizing all human resources and insurance needs, and working with the Executive Director and the Board of Directors. In her role as Chief Operating Officer, Melinda is a member of the Grants Management Network and continues to volunteer for non-profits to help them write grants. Prior to coming to the Foundation, she worked for the Naomi and Nehemiah Cohen Foundation, a small family foundation in the Washington, DC area which works on issues of social justice and helping those in need. While there, she reviewed grants, made site visits, wrote grant dockets, and presented all pertinent information to the board of directors for final review and selection of each grant recipient. Each year she awarded between four to five million in grants. Before her career move into philanthropy, she managed a gym and worked at a university recruiting medical students. Melinda has her BA in Communications from Waldorf College.

 



Legislative Update | Jessica Barker & Liz Darlison


Genetics and the BAP1 Gene in Mesothelioma

Moderator: Joseph R. Testa, PhD, FACMG

Dr. Testa is the Weg Chair in Human Genetics and Co-Leader of the Cancer Biology Program at Fox Chase Cancer Center in Philadelphia. Testa’s identification of consistent somatic and inherited mutations of tumor suppressor genes in mesothelioma has provided insights regarding genetic susceptibility, tumor formation/progression, and potential therapeutic targets. Included among this work is the discovery, with collaborator Michele Carbone, that mutations of BAP1 predispose to a novel tumor susceptibility syndrome marked by a high incidence of mesothelioma and certain other cancers. Testa and Fox Chase colleagues also cloned AKT oncogenes and demonstrated their frequent involvement in human cancer and therapeutic resistance. He has served in various capacities for IMIG and led an NIEHS/EPA team that evaluated factors impacting disease susceptibility to asbestos. He serves on the CDC’s National Mesothelioma Virtual Bank research evaluation panel and is a member of the TCGA-International Cancer Genome Consortium Mesothelioma Working Group.

Michele Carbone, MD, PhD

Michele Carbone, MD, PhD is Professor of Pathology and Director of the University of Hawai’i Cancer Center, a NCI-designated cancer center. Dr. Carbone worked at the National Institute of Health (NIH) from 1986 to 1994, at the University of Chicago and Loyola University Cancer Center of Chicago from 1994 until 2006, when he joined the University of Hawai’i.

Dr. Carbone discovered the mechanism of asbestos carcinogenesis and found that SV40, a virus that contaminated polio vaccine, synergizes with asbestos in causing mesothelioma. He studied an epidemic of mesothelioma in Cappadocia, Turkey, and demonstrated the existence of a genetic susceptibility factor. Recently, Dr. Carbone discovered a new cancer syndrome that linked BAP1 germline mutations to the development of mesothelioma, uveal melanoma and other cancers. His discoveries of extensive erionite exposure in North Dakota, USA led to cancer preventive measures and social and community improvements. Dr. Carbone published over 150 peer-reviewed papers. His research has been funded through grants from the NCI, ACS, and V-Foundation, and in 2008 he received the AACR-Landon

Innovator Award for International Collaboration in Cancer Research. Dr. Carbone has the honorary title of Knight of the Republic of Italy for his achievements in science and medicine.

Laura Ferris, MD

Dr. Laura Ferris is director of clinical trials and assistant professor of dermatology at the University Of Pittsburgh School Of Medicine. She completed her PhD in immunology at The Johns Hopkins University, her medical degree at The University of Maryland, and her dermatology residency and fellowship in cutaneous oncology at the University of Pittsburgh. Her interests include clinical investigation of psoriasis and pigmented skin lesions. Dr. Ferris specializes in the early detection of melanoma through screening and the use of technology. Within the field of mesothelioma research, she works in collaboration with the Cancer Center of Hawaii and is interested in the characterization of skin lesions that are found in some individuals that carry a BAP1 gene mutation, predisposing them to mesothelioma and other malignancies including cutaneous and ocular melanoma. Finding ways to non-invasively identify individuals with BAP1 mutations may allow this at-risk population to be counseled to avoid potential carcinogens including tobacco smoke, asbestos, and excess sun exposure and to undergo regular malignancy screening to improve early detection of cancer at a more treatable stage.

J. William Harbour, MD

J. William Harbour, MD, received his medical degree from Johns Hopkins University in 1990, followed by a residency in Ophthalmology at the Wills Eye Hospital in Philadelphia, and clinical fellowships in Vitreoretinal Diseases at the Bascom Palmer Eye Institute in Miami, and Ocular Oncology at the University of California in San Francisco. He obtained research fellowship training at the National Cancer Institute and in the Division of Molecular Oncology at Washington University. He was on the faculty of Washington University in St. Louis for 16 years and reached the position of Distinguished Professor of Ophthalmology and Visual Sciences. He is currently the Vice Chairman for Translational Research and Director of the Ocular Oncology Service at the Bascom Palmer Eye Institute of the University of Miami, where he has a joint appointment in the Sylvester Cancer Center and oversees a multi-disciplinary team of physicians and scientists studying the genetics and genomics of major eye cancers.

Jill A. Ohar, MD

Jill A. Ohar, MD, is Professor of Medicine in the Section on Pulmonary, Critical Care, Allergy & Immunologic Disease, at Wake Forest University School of Medicine, Winston-Salem, North Carolina. She is board certified by the American Board of Internal Medicine in internal medicine, critical care medicine, and pulmonary disease. Dr. Ohar earned her bachelor of science degree, graduating magna cum laude, from Muhlenberg College in Allentown, Pennsylvania, and her medical degree from Medical College of Pennsylvania in Philadelphia. Her postdoctoral training included an internship in obstetrics/gynecology at the Medical College of Pennsylvania and a residency in medicine at Medical College of Virginia in Richmond, where she completed a subsequent clinical fellowship in pulmonary diseases. She has published in such journals as Critical Care Medicine, Annals of Internal Medicine, and Chest, among others. She is a member of the American College of Physicians and the American Thoracic Society and a fellow of the American College of Chest Physicians.

Harvey Pass, MD

Harvey I. Pass, MD, is the Stephen E. Banner Professor of Thoracic Oncology, Vice Chairman, Research, Department of Cardiothoracic Surgery and Director, Division of Thoracic Surgery and Thoracic Oncology for the NYU Langone Medical Center and School of Medicine. Dr. Pass received his undergraduate education from Johns Hopkins University and graduated from Duke University Medical School. He trained in Cardiothoracic Surgery at the Medical University of South Carolina in Charleston, SC. He has led the Thoracic Oncology Programs at the NCI/NIH in Bethesda and at the Karmanos Cancer Institute in Detroit, Michigan. Dr. Pass has been continuously funded by grants from the National Cancer Institute, the Department of Veterans Affairs, the Department of Defense, or the CDC since 1998, and has co-authored over 380 original reports. Dr. Pass has received the NIH Directors Award, the Presidents Award for Clinical Research at Karmanos Cancer Institute, the Wagner Medal from the International Mesothelioma Interest Group, the Landon Award for International Science from the AACR, and the Pioneer Award from the Meso Foundation. He has been a Board Member of the International Association for the Study of Lung Cancer, the International Mesothelioma Interest Group, the Addario Foundation, and the Lung Cancer Alliance. Dr. Pass has been recognized as an America’s Top Doctor and Best Cancer Doctor by Castle Connoly’s Guide for the last 10 years.

Haining Yang, MD, PhD

Haining Yang, MD PhD, is Assistant Professor at the John A. Burns School of Medicine and the University of Hawai’i Cancer Center. She graduated from the School of Dentistry of Shandong Medical University, China in 1997, and received her Ph.D. in Biology from Shandong University in 2002. She moved to the US in 2003 and worked at the Cardinal Bernardin Cancer Center of the Loyola University, Chicago until 2006 when she joined the University of Hawai’i. Dr. Yang’s research focuses on mesothelioma pathogenesis and mineral fiber carcinogenesis. She discovered that asbestos causes the release of HMGB1, promoting and sustaining a chronic inflammatory process that eventually leads to mesothelioma development. Moreover, her discovery that HMGB1 also maintains the mesothelioma malignant phenotype steers the development of novel therapeutic approaches for this deadly cancer. She is also conducting clinical trials on early detection and prevention of mesothelioma. Dr. Yang’s research is funded by the National Cancer Institute, the V-Foundation and the Department of Defense, and the results of her work have been published in high-ranked journals, including PNAS, Cancer Research, Nature Genetics and others. Dr. Yang received EU Marie Curie Scholarship from the European Commission Marie Curie Actions Program in 2005, and she is one of the recipients of the Landon Award from the American Association for Cancer Research (AACR) in 2008.



2013 - Novel Research Findings | Mesothelioma

Moderator: Mary Hesdorffer, NP
Please see previous biography.

Tao Dao, MD, PhD

Dr. Tao Dao received her MD from Inner Mongolia Medical School and her PhD in immunology from Hyogo Medical School, Japan. After her post-doctoral study at Yale University Medical School in fundamental immunology, she joined Memorial Sloan Kettering Cancer Center, where she focuses on translational studies to develop peptide vaccines and antibody therapies against mesothelioma and leukemia. Along with Dr. David Scheinberg and Dr. Lee Krug, she and their team have successfully completed phase I clinical trials using WT1-peptide vaccines in patients with mesothelioma and leukemia. She is currently continuing this work via a phase II trial. She has also recently developed a novel, fully human mAb specific for WT1 peptide/HLA-A0201 complex that allows targeting intracellular oncoproteins that are usually inaccessible to traditional antibody therapy. She expects that this novel mAb therapy will prove to be an important innovation for the field of cancer therapy against mesothelioma and a wide range of human cancers.

Assunta De Rienzo, PhD

Dr. De Rienzo earned her PhD at the University of Naples in Italy. She completed her postdoctoral training with Dr. Joseph Testa at Fox Chase Cancer Center in Philadelphia. In 2006, Dr. De Rienzo joined the laboratory of Dr. Raphael Bueno in the Division of Thoracic Surgery, at the Brigham and Women’s Hospital in Boston, and, in 2008, was appointed Instructor in Surgery at Harvard Medical School. Dr. De Rienzo is currently the co-Director of the Thoracic Surgery Oncology Laboratory at the Brigham and Women’s Hospital in Boston, and her research focuses on the identification of targetable somatic mutations and/or pathways involved in mesothelioma for the identification of both therapeutic targets and predictive biomarkers.

Marc Ladanyi, MD

Dr. Marc Ladanyi is Attending Pathologist on Molecular Diagnostics Service in the Department of Pathology and Member in the Human Oncology & Pathogenesis Program at Memorial Sloan-Kettering

Cancer Center in New York City where he also holds the William Ruane endowed Chair in Molecular Oncology. For the past decade, Dr Ladanyi’s research group has been working on the genetics and molecular pathogenesis of pleural mesothelioma, most recently identifying the BAP1 gene as a key mutated gene in this cancer. Dr Ladanyi also co-directs The Cancer Genome Atlas (TCGA) group at MSKCC, part of the NCI/NHGRI TCGA network and is one of the leaders of the new TCGA Pleural Mesothelioma genomics project.

Liang-Chuan Wang, PhD

Dr. Liang-Chuan Wang received his Ph.D. in New Zealand in Cancer Pharmacology. As a PhD candidate, he was appointed as an assistant research fellow, which automatically transited into a postdoctoral position once he obtained his PhD title where he was in charge of technical staff and graduate students in a R01-equivalent project in New Zealand. He is now a post-doctoral fellow in the Thoracic Oncology Research Laboratory at Penn where his initial work focused on viral oncotherapy of lung cancer and mesothelioma. He has been highly productive, with a total of 20 peer-reviewed journal articles, and 4 more in submission, to date. Dr. Wang’s long term goals are to become an independent researcher, and establish his academic career in the United States with a major focus on mesothelioma research.

Nadia Zaffaroni, PhD

Dr. Zaffaroni graduated with honors in Biological Sciences at the University of Milan in 1980 and received her PhD in 1990 from the same University. She is Director of the Molecular Pharmacology Unit in the Department of Experimental Oncology at the National Cancer Institute of Milan, Italy. From 2006 to 2009, she served as Chairperson of the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer (EORTC). Her main area of investigation concerns translational research and is focused on the definition of novel biomarkers (mainly related to telomere maintenance mechanisms and apoptosis/autophagy pathways) and the identification and validation of new therapeutic targets. In the context, she has recently focused on the expression and functional role of microRNAs in selected tumor types, including peritoneal mesothelioma, with the aim to identify novel therapeutic targets for the disease. She has authored over 170 peer-reviewed journal articles.



Pharma Speaks Up

Moderator: Lee M. Krug, MD

Lee M. Krug, MD, is an Associate Attending Physician in the Division of Thoracic Oncology, Department of Medicine at Memorial Sloan-Kettering Cancer Center in New York, New York where he completed a fellowship and chief fellowship in medical oncology. Dr. Krug is the Director of the Mesothelioma Program at Memorial Sloan-Kettering Cancer Center. Dr. Krug has investigated multimodality approaches for patients with early stage malignant pleural mesothelioma. He led a multicenter U.S. trial of induction chemotherapy before extrapleural pneumonectomy, and he has a current study testing the feasibility of chemotherapy followed by pleural radiation. Dr. Krug also has a strong interest in novel therapeutics for patients with more advanced disease. He conducted a phase I trial with a WT-1 peptide vaccine, and he was awarded a grant from the Department of Defense to conduct a randomized phase II trial with this vaccine. He is also the principal investigator of an international, phase III trial of a histone deacetylase inhibitor, vorinostat. Dr. Krug led the committee for the National Comprehensive Cancer Network (NCCN) that established treatment guidelines for mesothelioma. He is the chairman of the Scientific Advisory Board at the Meso Foundation and also serves on the Board of Directors.

Julie Maltzman, MD - Morphotek

Dr. Maltzman is the Senior Medical Director and medical lead for the Thoracic Oncology program at Morphotek, an Eisai subsidiary. Under her purview, she directs drug development strategies for two monoclonal antibodies in two disease settings: NSCLC and Mesothelioma. Dr. Maltzman completed her Internal Medicine residency at the University of Chicago, Pritzker. She then completed her Hematology Oncology fellowship at the University of Pennsylvania. Following her training, she remained on faculty for a number of years before moving to industry. Dr. Maltzman has been in the pharmaceutical industry for 8 years, with nearly 6 years in large pharma and over 2 years in biotech. Throughout her time in the pharmaceutical industry, Dr. Maltzman maintains a current and active medical license and continues to treat breast cancer patients at the Philadelphia VA hospital associated with the University of Pennsylvania one day a week as a volunteer.

Aimee Murphy – Aduro BioTech, Inc.

Aimee Murphy is the Director of Clinical Operations of Aduro BioTech, Inc. She has more than 12 years of experience in all phases of clinical research and trial management, with a focus on therapeutic and prophylactic vaccines for cancer and infectious diseases. While at Cerus Corporation and Anza Therapeutics, she managed the first Phase 1 studies for what are now Aduro's therapeutic vaccines. Prior to working with Aduro’s platform, she worked at VaxGen for 6 years on the world's first Phase 3 prophylactic vaccine trials for HIV-1 as well as vaccine trials for anthrax and smallpox. Prior to working in clinical development, Ms. Murphy worked in Quality Assurance at Bayer Pharmaceuticals. She holds a BS in Biology from Pepperdine University.



Mesothelioma Fundraising | How to organize events and raise funds

Shelly Kozicki

Shelly has been involved with the Meso Foundation for over 14 years, since her dear husband Craig received his devastating diagnosis. Shelly lovingly cared for Craig for 11 years before he lost his battle with mesothelioma in April, 2009. She has dedicated her life to finding a cure, and has taken an active role in the mesothelioma community. Shelly is the first person to start a named grant in honor of her husband Craig, raising $100,000 to fund the first Craig Kozicki Research Grant in 2007. She has hosted or helped host trivia nights, golf tournaments, Quartermanias, letter writing campaigns and other events to support the Meso Foundation. Shelly has now funded two $100,000 Craig Kozicki Research Grants and is well on her way to funding a third. Shelly has raised more than $250,000 for mesothelioma research. Shelly’s hard work and dedication has been an inspiration to members of the community that have followed her lead and funded named grants for their loved ones.

Erica Ruble

Erica Leigh Ruble is the Fundraising Coordinator for the Mesothelioma Applied Research Foundation. She is also an estate planning lawyer from Fort Lauderdale, Florida. Erica received her JD from Nova Southeastern University Law School and her MA and BA in Communication from the University of Central Florida. Erica’s life was forever changed when her dad, Lance, was diagnosed with pleural mesothelioma on August 7, 2007. Determined to get well, he had chemotherapy, surgery, and radiation in 10 months. He passed away shortly after treatment, on August 16, 2008. Watching her dad lose his life to such a painful disease ignited a fire inside of her to search for better treatments for mesothelioma patients. Though her dad was gone, he embodied the meaning of LIFE. It is his spirit that lives on in her to help others. Erica is committed to a life-long contribution to fighting mesothelioma. She and her family fund the Lance S. Ruble Memorial Grant which contributes donations yearly to mesothelioma research. By promoting advocacy, awareness, and research, Erica has found a way to channel her pain to help others. It is her life’s mission to eradicate the vicious effects of this orphan disease.



Conversations with the Mesothelioma Community


Legal Panel

Moderated by Erica Ruble

 


Part 1: Multidisciplinary panel to achieve the best possible outcome for mesothelioma patients

Part 2: Multidisciplinary panel to achieve the best possible outcome for mesothelioma patients

Meso Foundation: Who we are and what we do | Mary Hesdorffer, NP

Information for New Patients | Mary Hesdorffer, Executive Director

Value, Worth and Merit of the Meso Foundation | Melinda Kotzian, COO

Legislative Update | Jessica Barker & Liz Darlison

Genetics and the BAP1 Gene in Mesothelioma

2013 - Novel Research Findings | Mesothelioma

Pharma Speaks Up

Mesothelioma Fundraising | How to organize events and raise funds

Conversations with the Mesothelioma Community

Legal Panel